Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Genetic variation of the gene COL17A1 and bullous pemphigoid in patients with neurodegenerative disorders.","authors":"Meltzanidou Parthena, Fantakis Antonios, Vassileva Snejina, Drenovska Kossara, Deretzi Georgia, Chatzopoulou Aikaterini, Kyriakou Aikaterini, Lazaridou Elisavet, Lambropoulos Alexandros, Syrrou Maria, Patsatsi Aikaterini","doi":"10.1111/jdv.20630","DOIUrl":"https://doi.org/10.1111/jdv.20630","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.","authors":"Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E French, Benjamin Kendziora","doi":"10.1111/jdv.20617","DOIUrl":"https://doi.org/10.1111/jdv.20617","url":null,"abstract":"<p><strong>Background: </strong>Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase III studies.</p><p><strong>Objective: </strong>To evaluate the relative efficacy and safety of biologics for HS in a network meta-analysis including available data from phase III trials.</p><p><strong>Methods: </strong>MEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate-to-severe HS. The odds ratios for reaching an HS Clinical Response 50 (HiSCR50) and for the occurrence of adverse events after 12-16 weeks were compared between treatments.</p><p><strong>Results: </strong>PIONEER I and II (adalimumab 40 mg weekly vs. placebo), SUNSHINE and SUNRISE (secukinumab 300 mg every 2 vs. 4 weeks vs. placebo) as well as BE HEARD I and II (bimekizumab 320 mg every 2 vs. 4 weeks vs. placebo) with 2731 patients were included. Adalimumab weekly was ranked most effective in reaching a HiSCR50 with significant superiority over secukinumab every 2 weeks (OR = 1.74; 95% confidence interval [CI]: 1.11-2.73) and 4 weeks (OR = 1.72; 95% CI: 1.09-2.7) and insignificant superiority over bimekizumab every 2 weeks (OR = 1.23; 95% CI: 0.74-2.06) and 4 weeks (OR = 1.25; 95% CI: 0.73-2.14). Adalimumab showed the fewest adverse events with significant superiority over bimekizumab every 2 weeks (OR = 0.52; 95% CI: 0.32-0.86) and insignificant superiority over bimekizumab every 4 weeks (OR = 0.79; 95% CI: 0.47-1.33) and secukinumab every 2 weeks (OR = 0.69; 95% CI: 0.45-1.07) and 4 weeks (OR = 0.71; 95% CI: 0.46-1.1).</p><p><strong>Conclusions: </strong>Among currently approved biologic agents for moderate-to-severe HS, adalimumab demonstrated the highest efficacy and safety in the first 12-16 weeks of treatment.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma.","authors":"Eva Muñoz Couselo, Carola Berking, Jean François Baurain, Serena Martelli, Ramon Arntz, Paola Savoia","doi":"10.1111/jdv.20629","DOIUrl":"https://doi.org/10.1111/jdv.20629","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erectile dysfunction in dermatology and venereology: From aetiopathogenic mechanisms to practical considerations for dermato-venereologists.","authors":"Andrei Tanasov, George-Sorin Tiplica","doi":"10.1111/jdv.20618","DOIUrl":"https://doi.org/10.1111/jdv.20618","url":null,"abstract":"<p><p>Erectile dysfunction (ED) is an often undiagnosed but significantly prevalent condition among male dermato-venereological patients, characterized by a complex pathophysiology and a substantial impact on quality of life. This review aimed to synthesize recent literature on the increased risk of ED in skin diseases, the underlying pathogenic mechanisms-including vasculogenic, endocrine, neurogenic, psychogenic and immunologic pathways-as well as the dermatologist's role in managing patients' sexual health. Inflammatory conditions (e.g. psoriasis, atopic dermatitis, lichen simplex chronicus and chronic hand eczema), infections (viral, bacterial and fungal, including sexually transmitted infections), autoimmune conditions (e.g. scleroderma and pemphigus) and disorders of the apocrine and eccrine glands (such as hidradenitis suppurativa) have all been linked to ED. The multi-systemic nature of many dermatologic diseases has become increasingly evident due to their associations with cardiovascular and metabolic comorbidities (atherosclerosis, hypertension, metabolic syndrome and vitamin D deficiency), central and peripheral neuropathies, endocrine disorders (hypogonadism and diabetes mellitus) or genito-urinary sequelae of sexually transmitted infections, while psychogenic ED further highlights the major mental health burden of skin conditions. Dermatologists are in the unique position to evaluate patients' sexual function and risk factors, investigate potential causes through accessible routine tests, prescribe impotence medication, consider erectile and overall sexual function in the dermatologic treatment choice and provide integrative lifestyle recommendations. Addressing sexual health in dermatologic practice offers significant benefits for both patients and healthcare systems, improving compliance, reducing logistical challenges and optimizing financial outcomes.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus.","authors":"Yousra Kanbar, Marie Jachiet, Chloé Grolleau, Estelle Charvet, Florence Cordoliani, Héloise Paugoy, Clémence Lepelletier, Sabine Karaa, Clémence Mauppin, Alizée Bozonnat, Charles Cassius, Thibault Mahevas, Jean-David Bouaziz","doi":"10.1111/jdv.20616","DOIUrl":"https://doi.org/10.1111/jdv.20616","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary syphilis with acute mastitis as the initial manifestation.","authors":"Ming-Ming Zhou, Long Geng","doi":"10.1111/jdv.20592","DOIUrl":"https://doi.org/10.1111/jdv.20592","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.","authors":"April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A Papp, Matthew J Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober","doi":"10.1111/jdv.20553","DOIUrl":"https://doi.org/10.1111/jdv.20553","url":null,"abstract":"<p><strong>Background: </strong>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.</p><p><strong>Objectives: </strong>To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis.</p><p><strong>Methods: </strong>PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily. At 52 weeks, patients enrolled in the LTE trial received open-label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib at any time. Clinical and patient-reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial.</p><p><strong>Results: </strong>In total, 1519 patients received ≥1 dose of deucravacitinib, with cumulative exposure of 4392.8 person-years (PY) through the data cut-off of 1 November 2023. Exposure-adjusted incidence rates (EAIRs)/100 PY of noted safety measures were comparable or decreased from the 1-year to 4-year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID-19) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib (n = 513), clinical and patient-reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%-50.0%], 4 years, 47.5% [42.6%-52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%-55.9%], 4 years, 49.4% [44.4%-54.4%]).</p><p><strong>Conclusions: </strong>Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel drugs for the management of recalcitrant erythema nodosum leprosum.","authors":"Mayra Ianhez, Ciro Martins Gomes, Aline Guimarães Grana, Carolina Talhari, Helio Amante Miot","doi":"10.1111/jdv.20622","DOIUrl":"https://doi.org/10.1111/jdv.20622","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alert on skin cancer risks linked to sunbeds.","authors":"Tiago R Matos, Myrto Trakatelli","doi":"10.1111/jdv.20584","DOIUrl":"https://doi.org/10.1111/jdv.20584","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying high-risk melanoma patients: The importance of acquiring a detailed family history.","authors":"M R Jansen, M El Moumni, B L van Leeuwen, P C van den Akker, E Rácz","doi":"10.1111/jdv.20601","DOIUrl":"https://doi.org/10.1111/jdv.20601","url":null,"abstract":"<p><strong>Background: </strong>It is essential to identify individuals with the highest risk of developing melanoma and to withhold individuals from surveillance with a low risk. However, international consensus on surveillance indications and the role of family history is still lacking.</p><p><strong>Objective: </strong>To provide more insight into the association between a family history of melanoma and the risk of developing melanoma.</p><p><strong>Methods: </strong>Adults who participated in the surveillance programme of the University Medical Center Groningen between June 1995 and November 2017 were retrospectively included. Participants were stratified into risk groups according to genetic assessment and family history following current Dutch guidelines: hereditary melanoma (risk group 1), familial melanoma (risk group 2) and their first-degree relatives (risk group 3), and other screening reasons (risk group 0). We included individuals fulfilling the 'possible familial melanoma' criteria (risk group 4) and their first-degree relatives (risk group 5), as evolving Dutch guidelines no longer recommend to screen these individuals. Melanoma incidence during follow-up was compared with the general population using standardized incidence ratios (SIRs), and the rate of developing melanomas was compared between risk groups and expressed as adjusted hazard ratios (aHRs).</p><p><strong>Results: </strong>In total, 224 participants were included (mean age 44.7 years; 56.7% female). During a median follow-up of 5.6 years (IQR, 3.7-7.8), a total number of 61 melanomas were diagnosed among 38 (17.0%) participants. The overall melanoma risk was significantly higher than in the general population (SIR 73). The rate of developing melanoma in risk group 4 was comparable to risk group 2 (aHR 1.27, p = 0.576).</p><p><strong>Conclusions: </strong>Stratification of individuals according to their family history of melanoma identifies those with a high risk of developing melanoma. Contrary to Dutch recommendations, surveillance should also be considered for melanoma patients fulfilling the 'possible familial melanoma' criteria.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}